Dr. Janni on the Future of Treatments for HER2-Positive Breast Cancer

Wolfgang Janni, MD, PhD
Published: Monday, May 01, 2017


  Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.

According to Janni, the APHINITY trial, is one of the trials that many are still excited about regarding treatments for HER2-positive breast cancer.

In terms of new agents, Janni states that it will be interesting to see data on other targeted agents such as CDK4/6 inhibitors in the HER2-positive setting. There is interesting data suggesting that this could be beneficial to patients.
 

  Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.

According to Janni, the APHINITY trial, is one of the trials that many are still excited about regarding treatments for HER2-positive breast cancer.

In terms of new agents, Janni states that it will be interesting to see data on other targeted agents such as CDK4/6 inhibitors in the HER2-positive setting. There is interesting data suggesting that this could be beneficial to patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x